Mon Oct 25 11:53:22 2021
EVENTS
 FREE
SOFTWARE
INSTITUTE

POLITICS
JOBS
MEMBERS'
CORNER

MAILING
LIST

NYLXS Mailing Lists and Archives
NYLXS Members have a lot to say and share but we don't keep many secrets. Join the Hangout Mailing List and say your peice.

DATE 2016-12-01

HANGOUT

2021-10-25 | 2021-09-25 | 2021-08-25 | 2021-07-25 | 2021-06-25 | 2021-05-25 | 2021-04-25 | 2021-03-25 | 2021-02-25 | 2021-01-25 | 2020-12-25 | 2020-11-25 | 2020-10-25 | 2020-09-25 | 2020-08-25 | 2020-07-25 | 2020-06-25 | 2020-05-25 | 2020-04-25 | 2020-03-25 | 2020-02-25 | 2020-01-25 | 2019-12-25 | 2019-11-25 | 2019-10-25 | 2019-09-25 | 2019-08-25 | 2019-07-25 | 2019-06-25 | 2019-05-25 | 2019-04-25 | 2019-03-25 | 2019-02-25 | 2019-01-25 | 2018-12-25 | 2018-11-25 | 2018-10-25 | 2018-09-25 | 2018-08-25 | 2018-07-25 | 2018-06-25 | 2018-05-25 | 2018-04-25 | 2018-03-25 | 2018-02-25 | 2018-01-25 | 2017-12-25 | 2017-11-25 | 2017-10-25 | 2017-09-25 | 2017-08-25 | 2017-07-25 | 2017-06-25 | 2017-05-25 | 2017-04-25 | 2017-03-25 | 2017-02-25 | 2017-01-25 | 2016-12-25 | 2016-11-25 | 2016-10-25 | 2016-09-25 | 2016-08-25 | 2016-07-25 | 2016-06-25 | 2016-05-25 | 2016-04-25 | 2016-03-25 | 2016-02-25 | 2016-01-25 | 2015-12-25 | 2015-11-25 | 2015-10-25 | 2015-09-25 | 2015-08-25 | 2015-07-25 | 2015-06-25 | 2015-05-25 | 2015-04-25 | 2015-03-25 | 2015-02-25 | 2015-01-25 | 2014-12-25 | 2014-11-25 | 2014-10-25 | 2014-09-25 | 2014-08-25 | 2014-07-25 | 2014-06-25 | 2014-05-25 | 2014-04-25 | 2014-03-25 | 2014-02-25 | 2014-01-25 | 2013-12-25 | 2013-11-25 | 2013-10-25 | 2013-09-25 | 2013-08-25 | 2013-07-25 | 2013-06-25 | 2013-05-25 | 2013-04-25 | 2013-03-25 | 2013-02-25 | 2013-01-25 | 2012-12-25 | 2012-11-25 | 2012-10-25 | 2012-09-25 | 2012-08-25 | 2012-07-25 | 2012-06-25 | 2012-05-25 | 2012-04-25 | 2012-03-25 | 2012-02-25 | 2012-01-25 | 2011-12-25 | 2011-11-25 | 2011-10-25 | 2011-09-25 | 2011-08-25 | 2011-07-25 | 2011-06-25 | 2011-05-25 | 2011-04-25 | 2011-03-25 | 2011-02-25 | 2011-01-25 | 2010-12-25 | 2010-11-25 | 2010-10-25 | 2010-09-25 | 2010-08-25 | 2010-07-25 | 2010-06-25 | 2010-05-25 | 2010-04-25 | 2010-03-25 | 2010-02-25 | 2010-01-25 | 2009-12-25 | 2009-11-25 | 2009-10-25 | 2009-09-25 | 2009-08-25 | 2009-07-25 | 2009-06-25 | 2009-05-25 | 2009-04-25 | 2009-03-25 | 2009-02-25 | 2009-01-25 | 2008-12-25 | 2008-11-25 | 2008-10-25 | 2008-09-25 | 2008-08-25 | 2008-07-25 | 2008-06-25 | 2008-05-25 | 2008-04-25 | 2008-03-25 | 2008-02-25 | 2008-01-25 | 2007-12-25 | 2007-11-25 | 2007-10-25 | 2007-09-25 | 2007-08-25 | 2007-07-25 | 2007-06-25 | 2007-05-25 | 2007-04-25 | 2007-03-25 | 2007-02-25 | 2007-01-25 | 2006-12-25 | 2006-11-25 | 2006-10-25 | 2006-09-25 | 2006-08-25 | 2006-07-25 | 2006-06-25 | 2006-05-25 | 2006-04-25 | 2006-03-25 | 2006-02-25 | 2006-01-25 | 2005-12-25 | 2005-11-25 | 2005-10-25 | 2005-09-25 | 2005-08-25 | 2005-07-25 | 2005-06-25 | 2005-05-25 | 2005-04-25 | 2005-03-25 | 2005-02-25 | 2005-01-25 | 2004-12-25 | 2004-11-25 | 2004-10-25 | 2004-09-25 | 2004-08-25 | 2004-07-25 | 2004-06-25 | 2004-05-25 | 2004-04-25 | 2004-03-25 | 2004-02-25 | 2004-01-25 | 2003-12-25 | 2003-11-25 | 2003-10-25 | 2003-09-25 | 2003-08-25 | 2003-07-25 | 2003-06-25 | 2003-05-25 | 2003-04-25 | 2003-03-25 | 2003-02-25 | 2003-01-25 | 2002-12-25 | 2002-11-25 | 2002-10-25 | 2002-09-25 | 2002-08-25 | 2002-07-25 | 2002-06-25 | 2002-05-25 | 2002-04-25 | 2002-03-25 | 2002-02-25 | 2002-01-25 | 2001-12-25 | 2001-11-25 | 2001-10-25 | 2001-09-25 | 2001-08-25 | 2001-07-25 | 2001-06-25 | 2001-05-25 | 2001-04-25 | 2001-03-25 | 2001-02-25 | 2001-01-25 | 2000-12-25 | 2000-11-25 | 2000-10-25 | 2000-09-25 | 2000-08-25 | 2000-07-25 | 2000-06-25 | 2000-05-25 | 2000-04-25 | 2000-03-25 | 2000-02-25 | 2000-01-25 | 1999-12-25

Key: Value:

Key: Value:

MESSAGE
DATE 2016-12-16
FROM From: "APhA's Pharmacy Today"
SUBJECT Subject: [Hangout-NYLXS] December 16,
From hangout-bounces-at-nylxs.com Sun Dec 18 04:09:30 2016
Return-Path:
X-Original-To: archive-at-mrbrklyn.com
Delivered-To: archive-at-mrbrklyn.com
Received: from www.mrbrklyn.com (www.mrbrklyn.com [96.57.23.82])
by mrbrklyn.com (Postfix) with ESMTP id BA570161312;
Sun, 18 Dec 2016 04:09:29 -0500 (EST)
X-Original-To: hangout-at-nylxs.com
Delivered-To: hangout-at-nylxs.com
Received: by mrbrklyn.com (Postfix, from userid 1000)
id 0A40C161311; Sun, 18 Dec 2016 04:09:24 -0500 (EST)
Resent-From: Ruben Safir
Resent-Date: Sun, 18 Dec 2016 04:09:24 -0500
Resent-Message-ID: <20161218090924.GA337-at-www.mrbrklyn.com>
Resent-To: hangout-at-nylxs.com
X-Original-To: ruben-at-mrbrklyn.com
Delivered-To: ruben-at-mrbrklyn.com
Received: from smtp.bayreuth.bluehornet.com (smtp.bayreuth.bluehornet.com
[67.216.227.202]) by mrbrklyn.com (Postfix) with ESMTP id AE4FA160E77
for ; Fri, 16 Dec 2016 08:24:42 -0500 (EST)
X-MSFBL: cnViZW5AbXJicmtseW4uY29tQGJheXJldXRoQGRlZmF1bHRAYm91bmNlLXVzZT1N
PTM2NzQ1NDE1NDg0PWVjaG80PTAxRUUyNDk0RjBDNjcyMEFGOTM3MDRGODRDRTU5 N0VB
DKIM-Signature: v=1; a=rsa-sha256; d=aphanet.org; s=s1024-1.bh; c=simple/simple;
q=dns/txt; i=-at-aphanet.org; t=1481894680;
h=From:Subject:Date:To:Mime-Version:Content-Type;
bh=dUP+DUZm67wTAG1e0jSl7+4CRD6UNq2ydvTq5dHv6xE=;
b=E1J1WckDDEzliQAz1+wYBwzAm2pVMirAt+kwXA9WE6bzmh+dE5gBVSBwBl40krwp
z5+YY9LnPfgpcPU/pKIYzsdKWogH6s0Q2ryszFWddhW2Xd7khr4GSuetZmRRkABC
T7HThI/kvzFFSoxxzG0VgapHb0UwinvWvWuW7r8p5X8=;
Received: from [172.24.32.92] ([172.24.32.92:44744] helo=localhost.localdomain)
by returnpath.bluehornet.com (envelope-from
)
(ecelerity 3.6.25.56547 r(Core:3.6.25.0)) with ESMTP
id AA/C8-13660-81BE3585; Fri, 16 Dec 2016 08:24:40 -0500
Message-ID:
Date: Fri, 16 Dec 2016 05:18:34 -0800
From: "APhA's Pharmacy Today"
To: =?UTF-8?B?UnViZW4gU2FmaXI=?=
X-Outgoing: bayreuth
Mime-Version: 1.0
X-UID: 33196
X-Content-Filtered-By: Mailman/MimeDel 2.1.17
Subject: [Hangout-NYLXS] December 16,
2016: 20 states accuse generic drug companies of price fixing
X-BeenThere: hangout-at-nylxs.com
X-Mailman-Version: 2.1.17
Precedence: list
Reply-To: PTdaily-at-aphanet.org, NYLXS Discussions List
List-Id: NYLXS Discussions List
List-Unsubscribe: ,

List-Archive:
List-Post:
List-Help:
List-Subscribe: ,

Content-Type: multipart/mixed; boundary="===============1784995272=="
Errors-To: hangout-bounces-at-nylxs.com
Sender: "hangout"



--===============1784995272==
Content-Type: multipart/alternative;
boundary="--5853e9aabaf2b-MultiPart-Mime-Boundary"



----5853e9aabaf2b-MultiPart-Mime-Boundary
Content-Type: text/plain; charset="utf-8"
Content-Disposition: inline
Content-Transfer-Encoding: 8bit



Pharmacy Today











View this email online.















DECEMBER 16, 2016




























20 states
accuse generic drug companies of price fixing
New York
Times (12/16/16) Thomas, Katie

Twenty
state attorneys general on Thursday filed an antitrust lawsuit
against six generic drug makers, as a wide-ranging investigation
into generic drug prices took its most significant turn yet. The
six companies are Mylan, Teva Pharmaceuticals, Citron Pharma,
Heritage Pharmaceuticals, Mayne Pharmaceuticals, and Aurobindo
Pharmaceuticals. The antitrust lawsuit and an ongoing federal
investigation will likely bring further political heat to the
generic drug sector. The... Read More







































?

Use of a 2-dose schedule for HPV vaccination - Updated
Recommendations







?

TSRI scientists discover potential drug candidate to suppress
pain and itch







?

DNA vaccines: Next defense against Zika, other invaders







?

'Zombie' outbreak caused by the synthetic cannabinoid
AMB-FUBINACA in New York





















?

Express Scripts sees no let-up in drug pricing chatter







?

Walgreens eyes more efficient health care







?

Preloading alkalinized lidocaine in ETT cuff reduces emergence
cough after GA





















?

Plan to Reduce Medicare Drug Costs Is Withdrawn After
Bipartisan Criticism







?

Merck wins record $2.5 billion patent verdict against Gilead







?

GOP plans to replace health care law with 'universal access'







?

Regulating off-label promotion - A critical test









































?

Rhodiola for fatigue and depression shows mixed results












?

FDA approves Jardiance (empagliflozin) to reduce the risk of
cardiovascular death in adult patients with type 2 diabetes
mellitus and cardiovascular disease












?

APhA has resources you need on opioids and pain management












?

Impact of a telephonic outreach program on medication adherence
in Medicare Advantage Prescription Drug (MAPD) plan beneficiaries



































20 states accuse generic drug
companies of price fixing
New York Times (12/16/16) Thomas,
Katie

Twenty state attorneys general on
Thursday filed an antitrust lawsuit against six generic drug
makers, as a wide-ranging investigation into generic drug prices
took its most significant turn yet. The six companies are Mylan,
Teva Pharmaceuticals, Citron Pharma, Heritage Pharmaceuticals,
Mayne Pharmaceuticals, and Aurobindo Pharmaceuticals. The
antitrust lawsuit and an ongoing federal investigation will
likely bring further political heat to the generic drug sector.
The new lawsuit goes out of its way to state that the "price
dynamic has changed for a large number of generic drugs," and
that "prices for generic drugs have uncharacteristically
risen-some have skyrocketed-for no apparent reason, sparking
outrage from public officials, payers, and consumers across the
country whose costs have doubled, tripled, or in some case
increased up to 1,000% or more." George Jepsen, Connecticut's
attorney general, whose office started the inquiry that led to
the charges, expressed the belief that "this is just the tip of
the iceberg." While several other big generic drug companies have
received subpoenas, it is unclear where the inquiries will
eventually lead. The generic drug business is already on the
defensive and struggling to recover from a barrage of public
criticism in the past year over high prices.
Read More |

Return to Headlines




Use of a 2-dose schedule for
HPV vaccination - Updated Recommendations
Morbidity and Mortality Weekly
Report (12/16/16) Vol. 65, No. 49, P. 1405 Meites, Elissa; Kempe,
Allison; Markowitz, Lauri E.

At its October 2016 meeting, the
Advisory Committee on Immunization Practices (ACIP) agreed to
promote a 2-dose vaccination schedule for human papillomavirus
(HPV). Licensed HPV vaccines in the United States to protect
against infection, genital warts, and some associated cancers to
date have been administered according to a 3-dose timetable; but
new clinical trial data support a 2-dose application. After
spending a year weighing the evidence for and against the
alternative protocol, which indicated that a 2-dose series would
work as well as a 3-dose series if administered before age 15 but
would be more cost-effective, ACIP approved new recommendations.
Under them, both boys and girls who start the vaccination process
from 9-14 years old should be put on the 2-dose schedule, with
the second dose administered 6-12 months after the first. The new
guidelines continue to recommend 3-dose vaccination for
adolescents and young adults who begin the series from 15-26
years as well as for people with compromised immune systems. The
second dose for these individuals should be administered 1-2
months after the first dose and the final dose should be received
6 months after the initial dose.
Read More |

Return to Headlines

TSRI scientists discover
potential drug candidate to suppress pain and itch
News-Medical.net (12/01/2016)

A team from The Scripps Research
Institute (TSRI) has introduced a kappa opioid receptor (KOR)
agonist that promises to relieve pain and itch while avoiding the
undesirable properties of similar agents. Drugs that target KORs
tend to sap the body's supply of the neurotransmitter dopamine,
subsequently triggering adverse events like sedation and anxiety.
Researchers at TSRI's Florida campus, however, have developed a
"biased" KOR agonist that can preferentially activate certain
pathways over others. Comparing triazole 1.1 and a conventional,
selective KOR agonist in rodent models, they demonstrated that
triazole 1.1 was able to suppress pain and itch while avoiding
unwanted adverse effects. "This adds to the mounting evidence
that shows analgesic effects can be separated from the sedative
and dysphoric effects by altering how the agonist engages the
receptor," explained first study author Tarsis Brust. KORs also
do not produce a "high" or elevated risk for overdose, making a
biased KOR agonist a good candidate for treating pain and itch
without the risk of abuse.
Read More |

Return to Headlines

DNA vaccines: Next defense
against Zika, other invaders
Wall Street Journal (12/16/16)
McKay, Betsy; Loftus, Peter

The Zika epidemic is accelerating
work on experimental DNA vaccines, which could turn out to be
America's best defense against infectious-disease outbreaks that
now spread around the world with alarming speed, fueled by rising
populations and global travel. These vaccines, made with
synthetic DNA, can be developed and manufactured quickly.
Researchers in the U.S. and Canada have injected dozens of
volunteers in the past few months with two competing DNA vaccines
intended to provide immunity to the Zika virus. Inovio
Pharmaceuticals is in a race to market its vaccine and
accompanying "electroporation device," a tool the size of an
electric toothbrush that uses a jolt of electricity to help usher
the firm's DNA vaccine into human cells. NIH is pursuing its own
DNA vaccine for Zika in a trial that began this summer.
Conventional vaccines made from viral and bacterial invaders
trigger the creation of antibodies. Experimental DNA vaccines
instruct the body to make proteins that resemble the invaders and
set off the body's defenses.
Read More |

Return to Headlines

'Zombie' outbreak caused by
the synthetic cannabinoid AMB-FUBINACA in New York
New England Journal of Medicine
(12/14/16) Adams, Axel J.; Banister, Samuel D.; Irizarry,
Lisandro; et al.

The dangers posed by new
psychoactive substances became clear this summer, after "AK-47 24
Karat Gold" produced a highly depressant response in residents
within a localized area of New York City. The behavior and
appearance of people who took the herbal "incense" product led
the media to characterize the occurrence as a "zombie outbreak."
By testing the blood of eight individuals sickened during the
mass intoxication and by also testing a sample of AK-47 24 Karat
Gold, experts identified the synthetic cannabinoid known as
AMB-FUBINACA as the culprit. The substance was present at a
potency level that explained the zombie-like adverse effects.
Although new "ultrapotent" manmade cannabinoids represent a
public health concern, cooperation among health professionals,
law enforcement, and clinical laboratories set the course for a
timely response to the threat in this particular case.
Read More |

Return to Headlines




Express Scripts sees no
let-up in drug pricing chatter
Reuters (12/14/16) Grover,
Natalie

Express Scripts Holding Co., the
largest PBM in the United States, predicts drug price inflation
will likely be restrained going into 2017 and that scrutiny into
pricing strategies will continue. Express Scripts CEO Tim
Wentworth said on a recent call with analysts that drug price
inflation will unlikely represent a "significant headwind" in
2017, and that the company has not seen the value of rebates
change recently. He added that more restraint can be expected
compared with the last couple of years. Separately, Wentworth
said the company believes drug prices are too high and "can and
should be lower."
Read More |

Return to Headlines

Walgreens eyes more efficient
health care
Chain Drug Review (12/12/16)
Walden, Geoff

Walgreens recognizes the
importance of pharmacy and is striving to make it more efficient.
Alex Gourlay, co-chief operating officer of Walgreens Boots
Alliance Inc., says one indication of inefficiency is
demonstrated by the great number of prescriptions that need
additional authorization on the way through a pharmacy, as well
as the number of filled prescriptions returned to the shelves
because they are not picked up by the patient. To address this,
the company has developed efficiency-focused partnerships,
including working with PBM Prime Therapeutics on both specialty
and mail-order pharmacy. Gourlay says the top value drivers in
specialty pharmacy are manufacturers and pharmacists, and as
biopharmaceutical development advances, there will undoubtedly be
more requests for pharmacy to be involved. In addition, with
manufacturers aiming to reinvest in more innovation without
raising drug prices excessively, "they want to make the supply
chain as efficient as possible." All of these aspects will
increase the prominence in health care of community pharmacy,
says Gourlay. Drug makers especially understand the value that
pharmacy brings in the form of access to maintenance drugs, and
recognize pharmacy can help get drugs "to the right people in a
personalized way," he says.
Read More |

Return to Headlines

Preloading alkalinized
lidocaine in ETT cuff reduces emergence cough after GA
Anesthesiology News (12/09/16)
Vlessides, Michael

Canadian researchers have found
that filling the endotracheal tube (ETT) cuff with alkalinized
lidocaine ahead of short surgeries quells emergence cough when
patients awaken from general anesthesia. Although alkalinized
lidocaine is already recognized for this ability, it was unclear
if the benefit was limited to longer procedures since the
analgesic typically takes 90-120 minutes to diffuse out of the
ETT cuff. The University of Montreal investigators tested the
idea of preloading the cuff at least 90 minutes prior to
operations expected to last 1 hour or less. Participants in the
study were randomly assigned to an ETT cuff that was inflated
either with alkalinized lidocaine or with saline. Just 12% of the
lidocaine patients experienced emergence cough, compared with 22%
of the saline patients. "So we can confidently say that
preloading alkalinized lidocaine in the ETT cuff significantly
diminishes cough in surgeries shorter than 90 minutes," said
pediatric anesthesiologist Papu Nath, MD, who reported the
research at the 2016 annual meeting of the Canadian
Anesthesiologists' Society.
Read More |

Return to Headlines




Plan to Reduce Medicare Drug
Costs Is Withdrawn After Bipartisan Criticism
New York Times (12/16/16) Pear,
Robert

The Obama administration said on
Thursday that it had scrapped one of its most significant efforts
to rein in spending on prescription drugs: a plan for a
nationwide experiment in which Medicare would have reduced
payments for many drugs given to patients in doctors' offices and
hospital clinics. Federal health officials withdrew the proposal
after it was criticized by pharmaceutical companies, doctors,
patients, and members of Congress from both parties. One of the
sharpest critics was Rep. Tom Price (R-GA), the man chosen by
President-elect Donald Trump to head HHS in his administration.
Ben Wakana, a spokesman for HHS, said that, after considering
public comments on a proposed rule, the agency had decided not to
move forward with the demonstration project, which was announced
in March. "The proposal was intended to test whether alternative
drug payment structures would improve the quality of patient care
and the value of Medicare drug spending," Wakana said. "While
there was a great deal of support from some, a number of
stakeholders expressed strong concerns." He added, "The
complexity of the issues and the limited time available led to
the decision not to finalize the rule at this time."
Read More |

Return to Headlines

Merck wins record $2.5
billion patent verdict against Gilead
Bloomberg (12/15/16) Yasiejko,
Christopher; Decker, Susan

Gilead Sciences on Thursday was
told by a federal jury to pay $2.54 billion to Merck for using a
patented invention as the basis for its blockbuster drugs for the
potentially deadly liver disease hepatitis C. The judgement
represents the biggest patent-infringement verdict in U.S.
history. The jury rejected Gilead's arguments that Merck's patent
is invalid. The judge in the case had already decided that
Merck's patent was infringed by Gilead's sofosbuvir (Sovaldi) and
ledipasvir; sofosbuvir (Harvoni), which account for more than
one-half the drugmaker's revenue. The infringement also was found
to be willful, meaning the judge could increase the damage award
by as much as three times the amount set by the jury. Gilead
pledged to appeal. The patent, issued in 2009, is for a compound
that Merck's Idenix unit contends is the basis for all major
treatments for hepatitis C.
Read More |

Return to Headlines

GOP plans to replace health
care law with 'universal access'
New York Times (12/16/16) Pear,
Robert; Kaplan, Thomas

House Republicans said on
Thursday that their goal in replacing the Affordable Care Act was
to guarantee "universal access" to health care and coverage, not
necessarily to ensure that everyone actually has insurance. The
Obama administration, congressional Democrats and advocacy groups
have focused on the 20 million people covered by the law, which
has pushed the percentage of Americans without health insurance
to record lows. The American Medical Association recently said
that "any new reform proposal should not cause individuals
currently covered to become uninsured." But House Republicans,
preparing for a rapid legislative strike on the law next month,
emphasize a different measure of success. "Our goal here is to
make sure that everybody can buy coverage or find coverage if
they choose to," a House leadership aide told journalists on the
condition of anonymity at a health care briefing organized by
Republican leaders. Republicans have an "ironclad commitment" to
repeal the law, the aide said, as lawmakers moved to discredit
predictions that many people would lose coverage. The suggestion
that 20 million people will lose coverage "is a big lie," said
Rep. Kevin Brady (R-TX), chairman of the House Ways and Means
Committee, after meeting with Republican members of his
committee. Republicans have not settled on the details or the
timing of their replacement plan.
Read More |

Return to Headlines

Regulating off-label
promotion - A critical test
New England Journal of Medicine
(12/15/16) Vol. 375, No. 24, P. 2313 Robertson, Christopher;
Kesselheim, Aaron S.

The Caronia court case, which
convicted a drug sales representative of promoting products for
off-label use but was overturned on appeal, is back in the
spotlight. The U.S. Court of Appeals for the Second Circuit
successfully argued in 2012 that verbal promotions were protected
by free speech, but cases that have surfaced in the meantime have
gone either way. Now, the logic underpinning the original Caronia
case is approaching its first real test outside of the Second
Circuit. The U.S. Court of Appeals for the First Circuit is
poised to review a related case, Facteau, which found two
executives guilty of marketing off-label use of risky medical
devices. Unlike the earlier decision, the jury was permitted to
consider actions as well as words in deciding whether the
products were unlawfully misbranded. Law professor Christopher
Robinson, JD, PhD, and Aaron S. Kesselheim-who is both an
attorney and a medical doctor-say that allowance is pointless
because if verbal sales pitches are unconstitutional under one
scenario, they are still illegal when coupled with nonverbal
promotion. They believe the First Circuit should discredit the
Second Circuit's reasoning, fearing that legal challenges and
other industry tactics-including a push to dilute FDA regulation
and proposed new guidelines for "responsible" promotion of
off-label drugs-mark the start of a deviation away from the basic
principles of the Food, Drug, and Cosmetic Act, which demands
that basic safety and efficacy standards be met for each intended
use. "The U.S. Constitution should not be misconstrued in such a
way as to undermine the primary functions of federal regulation
in this area: to protect patients and to create a high-quality
market for drugs and devices that is driven by science rather
than hype," Kesselheim and Robinson write.
Read More |

Return to Headlines



Abstract News © Copyright 2016
INFORMATION, INC.

This message was intended for: ruben-at-mrbrklyn.com
You were added to the system June 4, 2014.
For more information please follow the URL below:
http://echo4.bluehornet.com/p/iTdo2k6bMN

Follow the URL below to update your preferences or opt-out:
http://echo4.bluehornet.com/p/oTdo2k6bMN

To unsubscribe from future mailings, send an email to mailto:unsub-36745415484-echo4-01EE2494F0C6720AF93704F84CE597EA-at-emailsendr.net?Subject=Unsubscribe&body=Please%20remove%20me%20from%20further%20mailings
with "Unsubscribe" as the subject line.






----5853e9aabaf2b-MultiPart-Mime-Boundary
Content-Disposition: inline
MIME-Version: 1.0
Content-Type: text/plain; charset="utf-8"


[1]View this email online.
[2]test your know-immz
[3]Banner
DECEMBER 16, 2016
Top Story
logo

20 states accuse generic drug companies of price fixing
New York Times (12/16/16) Thomas, Katie
Twenty state attorneys general on Thursday filed an antitrust lawsuit
against six generic drug makers, as a wide-ranging investigation into
generic drug prices took its most significant turn yet. The six
companies are Mylan, Teva Pharmaceuticals, Citron Pharma, Heritage
Pharmaceuticals, Mayne Pharmaceuticals, and Aurobindo Pharmaceuticals.
The antitrust lawsuit and an ongoing federal investigation will likely
bring further political heat to the generic drug sector. The... [4]Read
More

[5]DEC 2016 BOM-w160

Drugs & Diseases
logo

?? [6]Use of a 2-dose schedule for HPV vaccination -- Updated
Recommendations

?? [7]TSRI scientists discover potential drug candidate to suppress
pain and itch

?? [8]DNA vaccines: Next defense against Zika, other invaders

?? [9]'Zombie' outbreak caused by the synthetic cannabinoid
AMB-FUBINACA in New York

Practice & Trends
logo

?? [10]Express Scripts sees no let-up in drug pricing chatter

?? [11]Walgreens eyes more efficient health care

?? [12]Preloading alkalinized lidocaine in ETT cuff reduces emergence
cough after GA

Laws, Regs & Rulings
logo

?? [13]Plan to Reduce Medicare Drug Costs Is Withdrawn After
Bipartisan Criticism

?? [14]Merck wins record $2.5 billion patent verdict against Gilead

?? [15]GOP plans to replace health care law with 'universal access'

?? [16]Regulating off-label promotion -- A critical test


News You Can Use

?? [17]Rhodiola for fatigue and depression shows mixed results
?? [18]FDA approves Jardiance (empagliflozin) to reduce the risk of
cardiovascular death in adult patients with type 2 diabetes mellitus
and cardiovascular disease
?? [19]APhA has resources you need on opioids and pain management
?? [20]Impact of a telephonic outreach program on medication adherence
in Medicare Advantage Prescription Drug (MAPD) plan beneficiaries
[21]VOD-300x250

[22]Dec 2016 PT

Top Story
20 states accuse generic drug companies of price fixing
New York Times (12/16/16) Thomas, Katie
Twenty state attorneys general on Thursday filed an antitrust lawsuit
against six generic drug makers, as a wide-ranging investigation into
generic drug prices took its most significant turn yet. The six
companies are Mylan, Teva Pharmaceuticals, Citron Pharma, Heritage
Pharmaceuticals, Mayne Pharmaceuticals, and Aurobindo Pharmaceuticals.
The antitrust lawsuit and an ongoing federal investigation will likely
bring further political heat to the generic drug sector. The new
lawsuit goes out of its way to state that the "price dynamic has
changed for a large number of generic drugs," and that "prices for
generic drugs have uncharacteristically risen--some have
skyrocketed--for no apparent reason, sparking outrage from public
officials, payers, and consumers across the country whose costs have
doubled, tripled, or in some case increased up to 1,000% or more."
George Jepsen, Connecticut's attorney general, whose office started the
inquiry that led to the charges, expressed the belief that "this is
just the tip of the iceberg." While several other big generic drug
companies have received subpoenas, it is unclear where the inquiries
will eventually lead. The generic drug business is already on the
defensive and struggling to recover from a barrage of public criticism
in the past year over high prices.
[23]Read More | [24]Return to Headlines
Drugs & Diseases
Use of a 2-dose schedule for HPV vaccination -- Updated Recommendations
Morbidity and Mortality Weekly Report (12/16/16) Vol. 65, No. 49, P.
1405 Meites, Elissa; Kempe, Allison; Markowitz, Lauri E.
At its October 2016 meeting, the Advisory Committee on Immunization
Practices (ACIP) agreed to promote a 2-dose vaccination schedule for
human papillomavirus (HPV). Licensed HPV vaccines in the United States
to protect against infection, genital warts, and some associated
cancers to date have been administered according to a 3-dose timetable;
but new clinical trial data support a 2-dose application. After
spending a year weighing the evidence for and against the alternative
protocol, which indicated that a 2-dose series would work as well as a
3-dose series if administered before age 15 but would be more
cost-effective, ACIP approved new recommendations. Under them, both
boys and girls who start the vaccination process from 9-14 years old
should be put on the 2-dose schedule, with the second dose administered
6-12 months after the first. The new guidelines continue to recommend
3-dose vaccination for adolescents and young adults who begin the
series from 15-26 years as well as for people with compromised immune
systems. The second dose for these individuals should be administered
1-2 months after the first dose and the final dose should be received 6
months after the initial dose.
[25]Read More | [26]Return to Headlines
TSRI scientists discover potential drug candidate to suppress pain and
itch
News-Medical.net (12/01/2016)
A team from The Scripps Research Institute (TSRI) has introduced a
kappa opioid receptor (KOR) agonist that promises to relieve pain and
itch while avoiding the undesirable properties of similar agents. Drugs
that target KORs tend to sap the body's supply of the neurotransmitter
dopamine, subsequently triggering adverse events like sedation and
anxiety. Researchers at TSRI's Florida campus, however, have developed
a "biased" KOR agonist that can preferentially activate certain
pathways over others. Comparing triazole 1.1 and a conventional,
selective KOR agonist in rodent models, they demonstrated that triazole
1.1 was able to suppress pain and itch while avoiding unwanted adverse
effects. "This adds to the mounting evidence that shows analgesic
effects can be separated from the sedative and dysphoric effects by
altering how the agonist engages the receptor," explained first study
author Tarsis Brust. KORs also do not produce a "high" or elevated risk
for overdose, making a biased KOR agonist a good candidate for treating
pain and itch without the risk of abuse.
[27]Read More | [28]Return to Headlines
DNA vaccines: Next defense against Zika, other invaders
Wall Street Journal (12/16/16) McKay, Betsy; Loftus, Peter
The Zika epidemic is accelerating work on experimental DNA vaccines,
which could turn out to be America's best defense against
infectious-disease outbreaks that now spread around the world with
alarming speed, fueled by rising populations and global travel. These
vaccines, made with synthetic DNA, can be developed and manufactured
quickly. Researchers in the U.S. and Canada have injected dozens of
volunteers in the past few months with two competing DNA vaccines
intended to provide immunity to the Zika virus. Inovio Pharmaceuticals
is in a race to market its vaccine and accompanying "electroporation
device," a tool the size of an electric toothbrush that uses a jolt of
electricity to help usher the firm's DNA vaccine into human cells. NIH
is pursuing its own DNA vaccine for Zika in a trial that began this
summer. Conventional vaccines made from viral and bacterial invaders
trigger the creation of antibodies. Experimental DNA vaccines instruct
the body to make proteins that resemble the invaders and set off the
body's defenses.
[29]Read More | [30]Return to Headlines
'Zombie' outbreak caused by the synthetic cannabinoid AMB-FUBINACA in
New York
New England Journal of Medicine (12/14/16) Adams, Axel J.; Banister,
Samuel D.; Irizarry, Lisandro; et al.
The dangers posed by new psychoactive substances became clear this
summer, after "AK-47 24 Karat Gold" produced a highly depressant
response in residents within a localized area of New York City. The
behavior and appearance of people who took the herbal "incense" product
led the media to characterize the occurrence as a "zombie outbreak." By
testing the blood of eight individuals sickened during the mass
intoxication and by also testing a sample of AK-47 24 Karat Gold,
experts identified the synthetic cannabinoid known as AMB-FUBINACA as
the culprit. The substance was present at a potency level that
explained the zombie-like adverse effects. Although new "ultrapotent"
manmade cannabinoids represent a public health concern, cooperation
among health professionals, law enforcement, and clinical laboratories
set the course for a timely response to the threat in this particular
case.
[31]Read More | [32]Return to Headlines
Practice & Trends
Express Scripts sees no let-up in drug pricing chatter
Reuters (12/14/16) Grover, Natalie
Express Scripts Holding Co., the largest PBM in the United States,
predicts drug price inflation will likely be restrained going into 2017
and that scrutiny into pricing strategies will continue. Express
Scripts CEO Tim Wentworth said on a recent call with analysts that drug
price inflation will unlikely represent a "significant headwind" in
2017, and that the company has not seen the value of rebates change
recently. He added that more restraint can be expected compared with
the last couple of years. Separately, Wentworth said the company
believes drug prices are too high and "can and should be lower."
[33]Read More | [34]Return to Headlines
Walgreens eyes more efficient health care
Chain Drug Review (12/12/16) Walden, Geoff
Walgreens recognizes the importance of pharmacy and is striving to make
it more efficient. Alex Gourlay, co-chief operating officer of
Walgreens Boots Alliance Inc., says one indication of inefficiency is
demonstrated by the great number of prescriptions that need additional
authorization on the way through a pharmacy, as well as the number of
filled prescriptions returned to the shelves because they are not
picked up by the patient. To address this, the company has developed
efficiency-focused partnerships, including working with PBM Prime
Therapeutics on both specialty and mail-order pharmacy. Gourlay says
the top value drivers in specialty pharmacy are manufacturers and
pharmacists, and as biopharmaceutical development advances, there will
undoubtedly be more requests for pharmacy to be involved. In addition,
with manufacturers aiming to reinvest in more innovation without
raising drug prices excessively, "they want to make the supply chain as
efficient as possible." All of these aspects will increase the
prominence in health care of community pharmacy, says Gourlay. Drug
makers especially understand the value that pharmacy brings in the form
of access to maintenance drugs, and recognize pharmacy can help get
drugs "to the right people in a personalized way," he says.
[35]Read More | [36]Return to Headlines
Preloading alkalinized lidocaine in ETT cuff reduces emergence cough
after GA
Anesthesiology News (12/09/16) Vlessides, Michael
Canadian researchers have found that filling the endotracheal tube
(ETT) cuff with alkalinized lidocaine ahead of short surgeries quells
emergence cough when patients awaken from general anesthesia. Although
alkalinized lidocaine is already recognized for this ability, it was
unclear if the benefit was limited to longer procedures since the
analgesic typically takes 90-120 minutes to diffuse out of the ETT
cuff. The University of Montreal investigators tested the idea of
preloading the cuff at least 90 minutes prior to operations expected to
last 1 hour or less. Participants in the study were randomly assigned
to an ETT cuff that was inflated either with alkalinized lidocaine or
with saline. Just 12% of the lidocaine patients experienced emergence
cough, compared with 22% of the saline patients. "So we can confidently
say that preloading alkalinized lidocaine in the ETT cuff significantly
diminishes cough in surgeries shorter than 90 minutes," said pediatric
anesthesiologist Papu Nath, MD, who reported the research at the 2016
annual meeting of the Canadian Anesthesiologists' Society.
[37]Read More | [38]Return to Headlines
Laws, Regs & Rulings
Plan to Reduce Medicare Drug Costs Is Withdrawn After Bipartisan
Criticism
New York Times (12/16/16) Pear, Robert
The Obama administration said on Thursday that it had scrapped one of
its most significant efforts to rein in spending on prescription drugs:
a plan for a nationwide experiment in which Medicare would have reduced
payments for many drugs given to patients in doctors' offices and
hospital clinics. Federal health officials withdrew the proposal after
it was criticized by pharmaceutical companies, doctors, patients, and
members of Congress from both parties. One of the sharpest critics was
Rep. Tom Price (R-GA), the man chosen by President-elect Donald Trump
to head HHS in his administration. Ben Wakana, a spokesman for HHS,
said that, after considering public comments on a proposed rule, the
agency had decided not to move forward with the demonstration project,
which was announced in March. "The proposal was intended to test
whether alternative drug payment structures would improve the quality
of patient care and the value of Medicare drug spending," Wakana said.
"While there was a great deal of support from some, a number of
stakeholders expressed strong concerns." He added, "The complexity of
the issues and the limited time available led to the decision not to
finalize the rule at this time."
[39]Read More | [40]Return to Headlines
Merck wins record $2.5 billion patent verdict against Gilead
Bloomberg (12/15/16) Yasiejko, Christopher; Decker, Susan
Gilead Sciences on Thursday was told by a federal jury to pay $2.54
billion to Merck for using a patented invention as the basis for its
blockbuster drugs for the potentially deadly liver disease hepatitis C.
The judgement represents the biggest patent-infringement verdict in
U.S. history. The jury rejected Gilead's arguments that Merck's patent
is invalid. The judge in the case had already decided that Merck's
patent was infringed by Gilead's sofosbuvir (Sovaldi) and ledipasvir;
sofosbuvir (Harvoni), which account for more than one-half the
drugmaker's revenue. The infringement also was found to be willful,
meaning the judge could increase the damage award by as much as three
times the amount set by the jury. Gilead pledged to appeal. The patent,
issued in 2009, is for a compound that Merck's Idenix unit contends is
the basis for all major treatments for hepatitis C.
[41]Read More | [42]Return to Headlines
GOP plans to replace health care law with 'universal access'
New York Times (12/16/16) Pear, Robert; Kaplan, Thomas
House Republicans said on Thursday that their goal in replacing the
Affordable Care Act was to guarantee "universal access" to health care
and coverage, not necessarily to ensure that everyone actually has
insurance. The Obama administration, congressional Democrats and
advocacy groups have focused on the 20 million people covered by the
law, which has pushed the percentage of Americans without health
insurance to record lows. The American Medical Association recently
said that "any new reform proposal should not cause individuals
currently covered to become uninsured." But House Republicans,
preparing for a rapid legislative strike on the law next month,
emphasize a different measure of success. "Our goal here is to make
sure that everybody can buy coverage or find coverage if they choose
to," a House leadership aide told journalists on the condition of
anonymity at a health care briefing organized by Republican leaders.
Republicans have an "ironclad commitment" to repeal the law, the aide
said, as lawmakers moved to discredit predictions that many people
would lose coverage. The suggestion that 20 million people will lose
coverage "is a big lie," said Rep. Kevin Brady (R-TX), chairman of the
House Ways and Means Committee, after meeting with Republican members
of his committee. Republicans have not settled on the details or the
timing of their replacement plan.
[43]Read More | [44]Return to Headlines
Regulating off-label promotion -- A critical test
New England Journal of Medicine (12/15/16) Vol. 375, No. 24, P. 2313
Robertson, Christopher; Kesselheim, Aaron S.
The Caronia court case, which convicted a drug sales representative of
promoting products for off-label use but was overturned on appeal, is
back in the spotlight. The U.S. Court of Appeals for the Second Circuit
successfully argued in 2012 that verbal promotions were protected by
free speech, but cases that have surfaced in the meantime have gone
either way. Now, the logic underpinning the original Caronia case is
approaching its first real test outside of the Second Circuit. The U.S.
Court of Appeals for the First Circuit is poised to review a related
case, Facteau, which found two executives guilty of marketing off-label
use of risky medical devices. Unlike the earlier decision, the jury was
permitted to consider actions as well as words in deciding whether the
products were unlawfully misbranded. Law professor Christopher
Robinson, JD, PhD, and Aaron S. Kesselheim--who is both an attorney and
a medical doctor--say that allowance is pointless because if verbal
sales pitches are unconstitutional under one scenario, they are still
illegal when coupled with nonverbal promotion. They believe the First
Circuit should discredit the Second Circuit's reasoning, fearing that
legal challenges and other industry tactics--including a push to dilute
FDA regulation and proposed new guidelines for "responsible" promotion
of off-label drugs--mark the start of a deviation away from the basic
principles of the Food, Drug, and Cosmetic Act, which demands that
basic safety and efficacy standards be met for each intended use. "The
U.S. Constitution should not be misconstrued in such a way as to
undermine the primary functions of federal regulation in this area: to
protect patients and to create a high-quality market for drugs and
devices that is driven by science rather than hype," Kesselheim and
Robinson write.
[45]Read More | [46]Return to Headlines
__________________________________________________________________

Abstract News ? Copyright 2016 [47]INFORMATION, INC.
[48]Powered by Information, Inc.
[49]cert-of-achieve-728x90
[50][USEMAP:footer.gif]

This message was intended for: [51]ruben-at-mrbrklyn.com
Please review our [52]privacy policy.

Please make certain that you can receive APhA communications by
adding [53]PTdaily-at-aphanet.org to your address book or Safe Senders
list.
? American Pharmacists Association (APhA). All Rights Reserved.
2215 Constitution Ave. NW, Washington, DC 20037
1-800-237-APhA

[54]Forward this to a friend | [55]Subscribe

[56]Update your preferences | [57]One-Click Unsubscribe

[N-Tdo2k6bMN-3CF43EF2E82566BE6EF267595DE8E526.jpg]

References

Visible links
1. http://social.bluehornet.com/p/vTdo2k6bMN
2. http://echo4.bluehornet.com/ct/91686577:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
3. LYNXIMGMAP:file://localhost/tmp/tmpQe9S2T.html#bannerMap
4. file:///tmp/tmpQe9S2T.html#901392
5. http://echo4.bluehornet.com/ct/91686579:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
6. file:///tmp/tmpQe9S2T.html#901345
7. file:///tmp/tmpQe9S2T.html#900711
8. file:///tmp/tmpQe9S2T.html#901380
9. file:///tmp/tmpQe9S2T.html#901223
10. file:///tmp/tmpQe9S2T.html#901256
11. file:///tmp/tmpQe9S2T.html#900989
12. file:///tmp/tmpQe9S2T.html#900402
13. file:///tmp/tmpQe9S2T.html#901397
14. file:///tmp/tmpQe9S2T.html#901333
15. file:///tmp/tmpQe9S2T.html#901384
16. file:///tmp/tmpQe9S2T.html#901225
17. http://echo4.bluehornet.com/ct/91686581:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
18. http://echo4.bluehornet.com/ct/91686583:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
19. http://echo4.bluehornet.com/ct/91686585:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
20. http://echo4.bluehornet.com/ct/91686587:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
21. http://echo4.bluehornet.com/ct/91686588:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
22. http://echo4.bluehornet.com/ct/91686589:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
23. http://echo4.bluehornet.com/ct/91686590:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
24. file:///tmp/tmpQe9S2T.html#top
25. http://echo4.bluehornet.com/ct/91686591:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
26. file:///tmp/tmpQe9S2T.html#top
27. http://echo4.bluehornet.com/ct/91686592:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
28. file:///tmp/tmpQe9S2T.html#top
29. http://echo4.bluehornet.com/ct/91686593:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
30. file:///tmp/tmpQe9S2T.html#top
31. http://echo4.bluehornet.com/ct/91686594:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
32. file:///tmp/tmpQe9S2T.html#top
33. http://echo4.bluehornet.com/ct/91686595:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
34. file:///tmp/tmpQe9S2T.html#top
35. http://echo4.bluehornet.com/ct/91686596:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
36. file:///tmp/tmpQe9S2T.html#top
37. http://echo4.bluehornet.com/ct/91686597:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
38. file:///tmp/tmpQe9S2T.html#top
39. http://echo4.bluehornet.com/ct/91686598:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
40. file:///tmp/tmpQe9S2T.html#top
41. http://echo4.bluehornet.com/ct/91686599:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
42. file:///tmp/tmpQe9S2T.html#top
43. http://echo4.bluehornet.com/ct/91686600:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
44. file:///tmp/tmpQe9S2T.html#top
45. http://echo4.bluehornet.com/ct/91686601:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
46. file:///tmp/tmpQe9S2T.html#top
47. http://echo4.bluehornet.com/ct/91686602:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
48. http://echo4.bluehornet.com/ct/91686603:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
49. http://echo4.bluehornet.com/ct/91686604:Tdo2k6bMN:m:1:2753392810:C4D099FCC06E32FED33A110C2626880D:r
50. LYNXIMGMAP:file://localhost/tmp/tmpQe9S2T.html#footerMap
51. mailto:ruben-at-mrbrklyn.com
52. http://www.pharmacist.com/privacy-policy
53. mailto:PTdaily-at-aphanet.org
54. http://echo4.bluehornet.com/forwardthis/ft.php?mID=57715747&em=ruben%40mrbrklyn.com&ch=fe90df003ff841eea1f

  1. 2016-12-01 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] FYI for Brooklynites and others
  2. 2016-12-01 Ruben Safir <ruben.safir-at-my.liu.edu> Subject: [Hangout-NYLXS] Fwd: Patrolling the Dark Net,
  3. 2016-12-03 Asher Elbein <aelbein-at-gmail.com> Subject: [Hangout-NYLXS] [dinosaur] Regarding Art Theft
  4. 2016-12-03 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] [dinosaur] Regarding Art Theft
  5. 2016-12-03 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Witner Labs
  6. 2016-12-03 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] the city for the people and by the people
  7. 2016-12-03 IEEE Engineering in Medicine and Biology Society <noreply-at-embs.org> Subject: [Hangout-NYLXS] HIMSS17 Early Bird Registration Deadline is
  8. 2016-12-04 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Nice lecture on Quantum Mechanics
  9. 2016-12-05 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Fwd: Tomorrow's Webinar - No Downtime Data
  10. 2016-12-05 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] http://www.lazarus-ide.org/
  11. 2016-12-05 Ruben Safir <ruben.safir-at-my.liu.edu> Subject: [Hangout-NYLXS] Fwd: [LIU Comp Sci] Nice possible project for NYLXS
  12. 2016-12-05 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Oh Look a real website
  13. 2016-12-05 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] information access, copyright wars and DRM
  14. 2016-12-05 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] More retarded news from the city that wants to push
  15. 2016-12-06 ruben safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] png data format
  16. 2016-12-06 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] png data format
  17. 2016-12-05 From: "Rijksmuseum" <rijksstudio-at-news.rijksmuseum.nl> Subject: [Hangout-NYLXS] Glorious food in Rijksstudio
  18. 2016-12-06 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] [Learn] png data format
  19. 2016-12-06 Christopher League <league-at-contrapunctus.net> Re: [Hangout-NYLXS] [Learn] png data format
  20. 2016-12-06 Christopher League <league-at-contrapunctus.net> Re: [Hangout-NYLXS] [Learn] png data format
  21. 2016-12-06 Christopher League <league-at-contrapunctus.net> Re: [Hangout-NYLXS] [Learn] png data format
  22. 2016-12-06 Christopher League <league-at-contrapunctus.net> Re: [Hangout-NYLXS] [Learn] png data format
  23. 2016-12-06 John Bowler <john.cunningham.bowler-at-gmail.com> Re: [Hangout-NYLXS] [png-mng-implement] 4 byte length storage
  24. 2016-12-06 John Bowler <john.cunningham.bowler-at-gmail.com> Re: [Hangout-NYLXS] [png-mng-implement] 4 byte length storage
  25. 2016-12-06 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] [png-mng-implement] 4 byte length storage
  26. 2016-12-06 Ruben Safir <mrbrklyn-at-panix.com> Re: [Hangout-NYLXS] [Learn] png data format
  27. 2016-12-06 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] [Learn] png data format
  28. 2016-12-06 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Fwd: Re: [luny-talk] Humble Bundle O'Reilly UNIX
  29. 2016-12-06 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Every face is tracked. Every footfall was
  30. 2016-12-06 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] JT's words
  31. 2016-12-06 James E Keenan <jkeen-at-verizon.net> Subject: [Hangout-NYLXS] The ny.pm talks I'd like to hear
  32. 2016-12-07 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Islam s fine
  33. 2016-12-09 Ruben Safir <ruben.safir-at-my.liu.edu> Subject: [Hangout-NYLXS] Fwd: Kindly Share the Free Journal
  34. 2016-12-09 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] good Shabbos All
  35. 2016-12-10 ruben safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Michael Kingsley and the Fascist in Office
  36. 2016-12-10 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] slow Vietnam like creep into Syrian civil war
  37. 2016-12-10 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] C++ returning lvalue references and pointers and
  38. 2016-12-10 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] a real live dinosaur tail found in the flesh
  39. 2016-12-10 Ruben Safir <ruben.safir-at-my.liu.edu> Subject: [Hangout-NYLXS] Movie of the Week
  40. 2016-12-10 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] Michael Kingsley and the Fascist in Office
  41. 2016-12-11 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] I knew as soon as I learned about dark matter that
  42. 2016-12-11 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] islam is your friend
  43. 2016-12-11 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] islam is your friend
  44. 2016-12-12 Ruben Safir <mrbrklyn-at-panix.com> Re: [Hangout-NYLXS] islam is your friendII
  45. 2016-12-12 Ruben Safir <mrbrklyn-at-panix.com> Re: [Hangout-NYLXS] islam is your friend III
  46. 2016-12-12 Ruben Safir <mrbrklyn-at-panix.com> Re: [Hangout-NYLXS] islam is your friend IV
  47. 2016-12-12 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] islam is your friend V
  48. 2016-12-12 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] islam is your friend VI
  49. 2016-12-12 Ruben Safir <mrbrklyn-at-panix.com> Re: [Hangout-NYLXS] islam is your friend VI
  50. 2016-12-12 Ruben Safir <mrbrklyn-at-panix.com> Re: [Hangout-NYLXS] islam is your friend VII
  51. 2016-12-12 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] islam is your friend VI
  52. 2016-12-11 Rick Tanner <leaf-at-real-time.com> Subject: [Hangout-NYLXS] [crossfire] Crossfire wiki offline for maintenance
  53. 2016-12-12 Gabor Szabo <gabor-at-szabgab.com> Subject: [Hangout-NYLXS] [Perlweekly] #281 - The holidays are upon us!
  54. 2016-12-12 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] islam is your friend VI
  55. 2016-12-12 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] islam is your friend VI
  56. 2016-12-12 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Minoan history
  57. 2016-12-13 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Death of the Sea Saw
  58. 2016-12-12 Nawaz Nazeer Ahamed <nawaz.nazeer.ahamed-at-oracle.com> Subject: [Hangout-NYLXS] MySQL Community Server 5.6.35 has been released
  59. 2016-12-13 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] C++ Threads Workshop
  60. 2016-12-13 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Summer Jobs
  61. 2016-12-14 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] islam is your friend VI
  62. 2016-12-14 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Fwd: Re: [dinosaur] Ceratopsid (Centrosaurinae:
  63. 2016-12-13 From: "Ruben.Safir" <ruben.safir-at-my.liu.edu> Subject: [Hangout-NYLXS] goldfinch
  64. 2016-12-14 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Apollo Moon Shot Photography
  65. 2016-12-14 From: "Mancini, Sabin (DFS)" <Sabin.Mancini-at-dfs.ny.gov> Subject: [Hangout-NYLXS] For Ruben ( + those in NYC Metro ) : Holiday Social
  66. 2016-12-14 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] islam is your friend VI
  67. 2016-12-14 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] islam is your friend VI
  68. 2016-12-14 Elfen Magix <elfen_magix-at-yahoo.com> Re: [Hangout-NYLXS] Apollo Moon Shot Photography
  69. 2016-12-15 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] islam is your friend VI
  70. 2016-12-15 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Your Santa Imam is here
  71. 2016-12-15 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] islam is your friend VI
  72. 2016-12-15 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] islam is your friend VI
  73. 2016-12-15 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Barak and Jerry Show
  74. 2016-12-15 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] Michael Kingsley and the Fascist in Office
  75. 2016-12-15 From: "American Museum of Natural History" <mat-at-amnh.org> Subject: [Hangout-NYLXS] Join the MAT Program Class of 2017
  76. 2016-12-16 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] this story is 5 years late on drug prices
  77. 2016-12-16 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Attacks at Cornel
  78. 2016-12-17 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  79. 2016-12-17 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  80. 2016-12-17 Ruben Safir <ruben.safir-at-my.liu.edu> Subject: [Hangout-NYLXS] Movie of the Week! Hello BOB!!
  81. 2016-12-17 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] anyone want to see Star Wars tonight?
  82. 2016-12-18 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  83. 2016-12-16 From: "APhA's Pharmacy Today" <PTdaily-at-aphanet.org> Subject: [Hangout-NYLXS] December 16,
  84. 2016-12-18 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  85. 2016-12-18 Ruben Safir <mrbrklyn-at-panix.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  86. 2016-12-18 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  87. 2016-12-18 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  88. 2016-12-18 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  89. 2016-12-18 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  90. 2016-12-18 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Look C++ is a functional programming language
  91. 2016-12-18 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  92. 2016-12-18 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  93. 2016-12-19 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  94. 2016-12-19 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  95. 2016-12-19 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] New Distros to try
  96. 2016-12-19 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] New Distros to try
  97. 2016-12-19 mayer ilovitz <pmamayeri-at-gmail.com> Re: [Hangout-NYLXS] New Distros to try
  98. 2016-12-19 ruben <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] New Distros to try
  99. 2016-12-19 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] New Distros to try
  100. 2016-12-19 ruben <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] another offbeat distro
  101. 2016-12-19 ruben <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] New Distros to try
  102. 2016-12-19 ruben <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] systemd critique et al
  103. 2016-12-19 ruben <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] New Distros to try
  104. 2016-12-19 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] New Distros to try
  105. 2016-12-19 From: "Ruben.Safir" <ruben.safir-at-my.liu.edu> Re: [Hangout-NYLXS] New Distros to try
  106. 2016-12-19 Gabor Szabo <gabor-at-szabgab.com> Subject: [Hangout-NYLXS] [Perlweekly] #282 - The White Camels are roaming
  107. 2016-12-19 From: "Mancini, Sabin (DFS)" <Sabin.Mancini-at-dfs.ny.gov> Re: [Hangout-NYLXS] New Distros to try: Please explain what the
  108. 2016-12-19 mayer ilovitz <pmamayeri-at-gmail.com> Re: [Hangout-NYLXS] New Distros to try: Please explain what the
  109. 2016-12-19 From: "Mancini, Sabin (DFS)" <Sabin.Mancini-at-dfs.ny.gov> Re: [Hangout-NYLXS] the issues with SystemD: why are they doing
  110. 2016-12-19 mayer ilovitz <pmamayeri-at-gmail.com> Re: [Hangout-NYLXS] the issues with SystemD: why are they doing
  111. 2016-12-19 ISOC-NY announcements <announce-at-lists.isoc-ny.org> Subject: [Hangout-NYLXS] [isoc-ny] JOB: Telecommunications Policy Specialist
  112. 2016-12-19 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  113. 2016-12-19 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  114. 2016-12-19 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] the issues with SystemD: why are they doing
  115. 2016-12-19 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] NYLXS Textbook Section
  116. 2016-12-19 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] NYLXS Textbook Section
  117. 2016-12-19 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] New Distros to try: Please explain what the
  118. 2016-12-19 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] New Distros to try: Please explain what the
  119. 2016-12-19 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] NYLXS Textbook Section
  120. 2016-12-19 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] Workshops -at- ACM/SPEC ICPE 2017 - Call for
  121. 2016-12-20 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] wow - just got an email from Ruth
  122. 2016-12-20 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] This Mayor is an IDIOT
  123. 2016-12-20 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  124. 2016-12-20 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  125. 2016-12-20 mayer ilovitz <pmamayeri-at-gmail.com> Re: [Hangout-NYLXS] This Mayor is an IDIOT
  126. 2016-12-20 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] This Mayor is an IDIOT
  127. 2016-12-20 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] This Mayor is an IDIOT
  128. 2016-12-20 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Ocean Parkway Protest!!
  129. 2016-12-20 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] The ever growing police state
  130. 2016-12-20 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Serious danger to state sovereignty and your right
  131. 2016-12-20 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] F'ing Mouse Pad
  132. 2016-12-20 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  133. 2016-12-20 IEEE Engineering in Medicine and Biology Society <noreply-at-embs.org> Subject: [Hangout-NYLXS] BHI'17 Registration Now Open!
  134. 2016-12-20 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] Serious danger to state sovereignty and your
  135. 2016-12-20 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  136. 2016-12-20 einker <eminker-at-gmail.com> Re: [Hangout-NYLXS] This Mayor is an IDIOT
  137. 2016-12-20 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] This Mayor is an IDIOT
  138. 2016-12-21 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] Serious danger to state sovereignty and your
  139. 2016-12-21 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  140. 2016-12-21 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] The fascinating case of Bernie Goetz
  141. 2016-12-21 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  142. 2016-12-21 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] The fascinating case of Bernie Goetz
  143. 2016-12-21 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  144. 2016-12-21 Ruben Safir <mrbrklyn-at-panix.com> Re: [Hangout-NYLXS] The fascinating case of Bernie Goetz
  145. 2016-12-21 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] Serious danger to state sovereignty and your
  146. 2016-12-21 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Thank god he is dead
  147. 2016-12-21 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Brooklyn Principal Shot to Death While Looking for
  148. 2016-12-21 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Marla Hanson recalls her nightmare
  149. 2016-12-21 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Official crime numbers in Kings County
  150. 2016-12-21 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] I'm sure it's a coincidence, part n+1
  151. 2016-12-21 ruben <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] LIU Brooklyn Campus Safety
  152. 2016-12-21 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] LIU Brooklyn Campus Safety
  153. 2016-12-21 Rick Moen <rick-at-linuxmafia.com> Subject: [Hangout-NYLXS] What California gets for Christmas
  154. 2016-12-21 From: "Amy at NTEN" <amy-at-nten.org> Subject: [Hangout-NYLXS] NTEN Connect: The Best NPTech Stories of 2016,
  155. 2016-12-21 IEEE Engineering in Medicine and Biology Society <noreply-at-embs.org> Subject: [Hangout-NYLXS] 2017 ISBI Call for Abstracts- Submission Deadline
  156. 2016-12-21 einker <eminker-at-gmail.com> Re: [Hangout-NYLXS] This Mayor is an IDIOT
  157. 2016-12-21 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] This Mayor is an IDIOT
  158. 2016-12-21 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Marnchester by the Sea
  159. 2016-12-21 mayer ilovitz <pmamayeri-at-gmail.com> Re: [Hangout-NYLXS] This Mayor is an IDIOT
  160. 2016-12-21 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] This Mayor is an IDIOT
  161. 2016-12-21 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] What California gets for Christmas
  162. 2016-12-21 Ruben Safir <mrbrklyn-at-panix.com> Re: [Hangout-NYLXS] This Mayor is an IDIOT
  163. 2016-12-21 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] This Mayor is an IDIOT
  164. 2016-12-22 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] the sorry state of this country and its bizarre
  165. 2016-12-22 From: "Mancini, Sabin (DFS)" <Sabin.Mancini-at-dfs.ny.gov> Re: [Hangout-NYLXS] What California gets for Christmas: Yeah but
  166. 2016-12-22 From: "Mancini, Sabin (DFS)" <Sabin.Mancini-at-dfs.ny.gov> Re: [Hangout-NYLXS] sorry state this country,
  167. 2016-12-22 From: "Mancini, Sabin (DFS)" <Sabin.Mancini-at-dfs.ny.gov> Re: [Hangout-NYLXS] This Mayor is an IDIOT | | Yeah,
  168. 2016-12-22 Ruben Safir <mrbrklyn-at-panix.com> Re: [Hangout-NYLXS] sorry state this country,
  169. 2016-12-22 From: "Mancini, Sabin (DFS)" <Sabin.Mancini-at-dfs.ny.gov> Re: [Hangout-NYLXS] Shelter Cove- which one ? There are two- one in
  170. 2016-12-22 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] Shelter Cove- which one ? There are two- one in
  171. 2016-12-22 From: "Mancini, Sabin (DFS)" <Sabin.Mancini-at-dfs.ny.gov> Re: [Hangout-NYLXS] And be aware you were an unexcused no-show
  172. 2016-12-22 Ruben Safir <ruben.safir-at-my.liu.edu> Re: [Hangout-NYLXS] And be aware you were an unexcused no-show
  173. 2016-12-22 From: "Mancini, Sabin (DFS)" <Sabin.Mancini-at-dfs.ny.gov> Re: [Hangout-NYLXS] And be aware you were an unexcused no-show
  174. 2016-12-22 Ruben Safir <mrbrklyn-at-panix.com> Re: [Hangout-NYLXS] And be aware you were an unexcused no-show
  175. 2016-12-22 From: "Mancini, Sabin (DFS)" <Sabin.Mancini-at-dfs.ny.gov> Re: [Hangout-NYLXS] We were talking about how you could transport
  176. 2016-12-23 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] And be aware you were an unexcused no-show
  177. 2016-12-23 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] Shelter Cove- which one ? There are two- one in
  178. 2016-12-23 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] This Mayor is an IDIOT | | Yeah,
  179. 2016-12-23 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] sorry state this country,
  180. 2016-12-23 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] What California gets for Christmas: Yeah but
  181. 2016-12-23 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Homeless have taken over 34th street
  182. 2016-12-23 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] the sorry state of this country and its bizarre
  183. 2016-12-23 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] the sorry state of this country and its bizarre
  184. 2016-12-23 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] HOPL (History of Programming Languages)
  185. 2016-12-23 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout-NYLXS] Tiny Compiler in many languages at
  186. 2016-12-24 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Chag Simaach
  187. 2016-12-24 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] jobs
  188. 2016-12-25 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Sanders and Socialism
  189. 2016-12-25 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Free Speach
  190. 2016-12-25 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Google and C++
  191. 2016-12-25 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Conflicts of Interest
  192. 2016-12-25 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] Syria wished you a Merry Christmas
  193. 2016-12-25 Rick Moen <rick-at-linuxmafia.com> Subject: [Hangout-NYLXS] Light even in the darkness
  194. 2016-12-25 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] Syria wished you a Merry Christmas
  195. 2016-12-26 Gabor Szabo <gabor-at-szabgab.com> Subject: [Hangout-NYLXS] [Perlweekly] #283 - Merry Christmas & Happy Hanukkah
  196. 2016-12-26 Gabor Szabo <gabor-at-szabgab.com> Subject: [Hangout-NYLXS] [Perlweekly] #283 - Merry Christmas & Happy Hanukkah
  197. 2016-12-27 From: "Ruben.Safir" <ruben.safir-at-my.liu.edu> Subject: [Hangout-NYLXS] Israel band, Iran Good
  198. 2016-12-27 mrbrklyn <mrbrklyn-at-panix.com> Subject: [Hangout-NYLXS] Israel band, Iran Good
  199. 2016-12-27 mrbrklyn <mrbrklyn-at-panix.com> Subject: [Hangout-NYLXS] International criminals, every jew
  200. 2016-12-27 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout-NYLXS] she's gone
  201. 2016-12-27 Rick Moen <rick-at-linuxmafia.com> Re: [Hangout-NYLXS] International criminals, every jew
  202. 2016-12-28 mrbrklyn <mrbrklyn-at-panix.com> Re: [Hangout-NYLXS] International criminals, every jew
  203. 2016-12-28 mrbrklyn <mrbrklyn-at-panix.com> Subject: [Hangout-NYLXS] can't find the damn ball anywhere here
  204. 2016-12-28 From: "Pharmacy Times" <enews-at-pharmacytimes.com> Subject: [Hangout-NYLXS] Xtampza(R) ER (oxycodone) Product Bulletin
  205. 2016-12-29 From: "Ruben.Safir" <ruben.safir-at-my.liu.edu> Subject: [Hangout-NYLXS] Police State gets one step closer

NYLXS are Do'ers and the first step of Doing is Joining! Join NYLXS and make a difference in your community today!